Search

Your search keyword '"Tredan O"' showing total 423 results
Start Over Author "Tredan O"
Sorry, I don't understand your search. ×
423 results on '"Tredan O"'

1. A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later

Author

Di Meglio, A., Havas, J., Pagliuca, M., Franzoi, M.A., Soldato, D., Chiodi, C.K., Gillanders, E., Dubuisson, F., Camara-Clayette, V., Pistilli, B., Ribeiro, J., Joly, F., Cottu, P.H., Tredan, O., Bertaut, A., Ganz, P.A., Bower, J., Partridge, A.H., Martin, A.L., Everhard, S., Boyault, S., Brutin, S., André, F., Michiels, S., Pradon, C., and Vaz-Luis, I.

Published
2024
Full Text
View/download PDF

3. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Author

Goetz, M.P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I.H., Campone, M., Chen, S.-C., Manso, L.M., Paluch-Shimon, S., Freedman, O.C., O’Shaughnessy, J., Pivot, X., Tolaney, S.M., Hurvitz, S.A., Llombart-Cussac, A., André, V., Saha, A., van Hal, G., Shahir, A., Iwata, H., and Johnston, S.R.D.

Published
2024
Full Text
View/download PDF

7. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Zhang, Q., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Shen, K., Yin, Y., Sun, T., Yang, J., Feng, J., Yan, M., Wang, Y., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Guarneri, V., Colleoni, M., Natoli, C., Cortesi, L., Placido, S., Gianni, L., Ferrau, F., Livi, L., Zambelli, A., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Pedersini, R., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Mailliez, A., Priou, F., Tredan, O., Dalenc, F., Perrin, C., Gligorov, J., Timar David, M., Dohollou, N., Teixeira, L., Brocard, F., Arnaud, A., Delaloge, S., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Pedrini, J., Aleixo, S., Hegg, R., Junior, R., Reinisch, M., Schmidt, M., Wenzel, C., Grischke, E.-M., Schneeweiss, A., Just, M., Harbeck, N., Schumacher, C., Peters, U., Fischer, D., Forstbauer, H., Liersch, R., Warner, E., Bouganim, N., Doyle, C., Price Hiller, J., Vandenberg, T., Pavic, M., Robinson, A., Roldan Urgoiti, G., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Uygun, K., Kaplan, M., Cubukcu, E., Wardley, A., Harries, M., Miles, D., Doval, D., Gupta, S., Mohapatra, P., Chatterjee, S., Ghadyalpatil, N., Singhal, M., Nag, S., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Fried, G., Ben Baruch, N., Katz, D., Hamilton, E., Kayali, F., Brufsky, A., Telli, M., Wright, G., Oyola, R., Rakowski, T., Graff, S., Tjulandin, S., Semiglazov, V., Aparicio, A., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Lopez, E., Yamashita, T., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Nakayama, T., Sagara, Y., Yanagita, Y., Kamada, Y., Kaneko, K., Kaen, D., Nervo, A., Eniu, A., Schenker, M., Priester, P., Melichar, B., Zimovjanova, M., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Aravantinos, G., Papadimitriou, C., Koumakis, G., Papandreou, C., Podolski, P., Tabane, K., André, F., Cameron, D., Barrios, C., Patel, S., Patre, M., Morales, L., Patel, S.L., Kaul, M., Barata, T., and O’Shaughnessy, J.

Published
2021
Full Text
View/download PDF

8. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A, investigators, ARIEL3, Buck, M, Dean, A, Friedlander, ML, Goh, JC, Harnett, P, Kichenadasse, G, Scott, CL, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, AM, Plante, M, Provencher, D, Weberpals, JI, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, RF, Scambia, G, Tamberi, S, Zamagni, C, Fong, PC, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, EM, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, SN, Clamp, A, Drew, Y, Gabra, HG, Jackson, D, Ledermann, JA, McNeish, IA, Parkinson, C, and Powell, M

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Orphan Drug, Clinical Research, Cancer, Genetics, Clinical Trials and Supportive Activities, Ovarian Cancer, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Aged, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Humans, Indoles, Internationality, Maintenance Chemotherapy, Middle Aged, Molecular Targeted Therapy, Neoplasm Recurrence, Local, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Risk Assessment, Survival Rate, Treatment Outcome, ARIEL3 investigators, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundRucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.MethodsIn this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0-1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete.FindingsBetween April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4-22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4-6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16-0·34]; p

Published
2017

9. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Author

Heudel, P., Chabaud, S., Perol, D., Flechon, A., Fayette, J., Combemale, P., Tredan, O., Desseigne, F., de la Fouchardiere, C., Boyle, H., Perol, M., Bachelot, T., Cassier, P., Avrillon, V., Terret, C., Michallet, A.-S., Neidhardt-Berard, E.-M., Nicolas-Virelizier, E., Dufresne, A., Belhabri, A., Brahmi, M., Lebras, L., Nicolini, F., Sarabi, M., Rey, P., Bonneville-Levard, A., Rochefort, P., Provensal, A.-M., Eberst, L., Assaad, S., Swalduz, A., Saintigny, P., Toussaint, P., Guillermin, Y., Castets, M., Coutzac, C., Meeus, P., Dupré, A., Durand, T., Crochet, H., Fervers, B., Gomez, F., Rivoire, M., Gregoire, V., Claude, L., Chassagne-Clement, C., Pilleul, F., Mognetti, T., Russias, B., Soubirou, J.-L., Lasset, C., Chvetzoff, G., Mehlen, P., Beaupère, S., Zrounba, P., Ray-Coquard, I., and Blay, J.-Y.

Published
2021
Full Text
View/download PDF

10. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Author

Piprot, C, Cals, L, Chaigneau, L, Demarchi, F, N'Guyen, T, Stein, U, Villanueva, C, Bréau, JL, Chouahnia, AK, Saintigny, P, Boué, F, deSaint-Hilaire, P, Guimont, I, Grossat, N, Valenza, B, Lévy, E, Médioni, J, Delbaldo, C, Grenier, J, Pouessel, D, Lavau-Denès, S, Falandry, C, Fournel-Fédérico, C, Freyer, G, Tartas, S, Trillet-Lenoir, V, Bons, F, Auclerc, G, Chièze, S, Raban, N, Tournigand, C, Trager-Maury, S, Bousquet, G, Cuvier, C, Giacchetti, S, Hocini, A, LeMaignan, C, Misset, JL, Avenin, D, Beerblock, C, Gligorov, J, Rivera, P, Roché, H, Bougnoux, P, Hajjaji, N, Capitain, O, Delva, R, Maillart, P, Soulié, P, Bonnefoi, H, Durand, M, Madranges, N, Mauriac, L, Chollet, P, Dillies, AF, Durando, X, Ferrière, JP, Mouret-Reynier, C, Nabholtz, JM, Van Praagh, I, Cottu, P, Diéras, V, Durieux, A, Galotte, M, Girre, V, Henry, S, Iurisci, I, Jouve, M, Laurence, V, Mignot, L, Piperno-Neumann, S, Tresca, P, Coudert, B, Ferrant, E, Mayer, F, Vanneuville, AC, Bonneterre, J, Servent, V, Vanlemmens, L, Vennin, P, Guastalla, JP, Biron, P, Dupuy-Brousseau, L, Lancry, L, Ray-Coquard, I, Rebattu, P, Trédan, O, Extra, JM, Rousseau, F, Tarpin, C, Fabbro, M, Luporsi, E, Uwer, L, Weber, B, Berton-Rigaud, D, Bourbouloux, E, Campone, M, Ferrero, JM, Follana, P, Largillier, R, Mari, V, Costa, B, Curé, H, Eymard, JC, Jovenin, N, Lebrun, D, Meunier, J, Yazbek, G, Gedoin, D, Laguerre, B, Lefeuvre, C, Vauléon, E, Chevrier, A, Guillemet, C, Leheurteur, M, Rigal, O, Tennevet, I, Veyret, C, Brain, E, Guiterrez, M, Mefti-Lacheraf, F, Petit, T, Dalenc, F, Gladieff, L, André, F, Delaloge, S, Domont, J, Ezenfis, J, Spielmann, M, Guillet, P, Boulanger, V, Provençal, J, Stefani, L, Alliot, C, Ré, D, Bellaiche-Miccio, C, Boutan-Laroze, G, Vanica, R, Dion, P, Sadki-Benaoudia, G, Marti, A, Villing, AL, Slama, B, Dutel, JL, Nguyen, S, Saad, R, Arsène, O, Merad-Boudia, Z, Orfeuvre, H, Egreteau, J, Goudier, MJ, Lamy, R, Leduc, B, Sarda, C, Salles, B, Agostini, C, Cauvin, I, Dufresne, A, Mangold, M, Lebouvier-Sadot, S, Audhuy, B, Barats, JC, Cluet-Dennetière, S, Zylberait, D, Netter, G, Gautier-Felizot, L, Cojean-Zelek, I, Plantade, A, Vignot, S, Guardiola, E, Marti, P, deHartingh, I, Diab, R, Dietmann, A, Ruck, S, Portois, C, Oddou-Lagranière, S, Campos-Gazeau, F, Bourcier, A, Priou, F, Geay, JF, Mayeur, D, Gabez, P, ElAmarti, R, Combe, M, Raichon-Patru, P, Amsalhem, P, Dauba, J, Paraiso, D, Guinet, F, Duvert, B, Litor, M, Kara-Slimane, F, Bichoffe, A, Denizon, N, Soyer, P, Morvan, F, Van-Hulst, S, Vincent, L, Alleaume, C, Ibanez-Martin, P, Youssef, A, Tadrist, Z, Carola, E, Pourny, C, Toccanier, JF, Al-Aukla, N, Mahour-Bacha, K, Salvat, J, Nouyrigat, P, Clippe, S, Gouttebel, MC, Vedrine, L, Clavreul, G, Collard, O, Mille, D, Goubely, Y, Hervé, R, Kirscher, S, Plat, F, Delecroix, V, Ligeza-Poisson, V, Coeffic, D, Fric, D, Garnier, C, Leyronnas, C, Kreitman, T, Teissier, E, Martin, P, Rohart deCordoue, S, ElKouri, C, Ramée, JF, Laporte, C, Bernard, O, Altwegg, T, Darut-Jouve, A, Dujols, JP, Darloy, F, Giraud, C, Pottier-Kyndt, V, Achour, N, Drony, S, Moriceau, M, Sarrazin, C, Legueul, JC, Mandet, J, Besson, D, Hardy-Bessard, AC, Cretin, J, Houyau, P, Achille, E, Genêt, D, Thévenot, H, Moran-Ribon, A, Pavlovitch, JM, Ardisson, P, Moullet, I, Couderc, B, Fichet, V, Burki, F, Auliard, A, Levaché, CB, Cailleux, P, Schaeffer, F, Albin, N, Sévin-Robiche, D, Domas, J, Ellis, S, Montcuquet, P, Baumont, GA, Bégue, M, Gréget, S, Ratoanina, JL, Vanoli, A, Bielsa, C, Bonichon-Lamichhane, M, Jaubert, D, Laharie-Mineur, H, Alcaraz, L, Legouffe, E, Bourgeois, H, Cartron, G, Denis, F, Dupuis, O, Ganem, G, Roche-Forestier, S, Delzenne, L, Chirat, E, Baticle, JL, Béguier, E, Jacquot, S, Janssen, E, Lauché, H, LeRol, A, Chantelard, JP, L'Helgoualc'h, GA, Antoine, EC, Kanoui, A, Llory, JF, Vannetzel, JM, Vignoud, J, Bruna, C, Facchini, T, Moutel-Corviole, K, Voloch, A, Ghoul, A, Loiseau, D, Barbet, N, Dohollou, N, Yakendji, K, Pivot, Xavier, Romieu, Gilles, Debled, Marc, Pierga, Jean-Yves, Kerbrat, Pierre, Bachelot, Thomas, Lortholary, Alain, Espié, Marc, Fumoleau, Pierre, Serin, Daniel, Jacquin, Jean-Philippe, Jouannaud, Christelle, Rios, Maria, Abadie-Lacourtoisie, Sophie, Venat-Bouvet, Laurence, Cany, Laurent, Catala, Stéphanie, Khayat, David, Gambotti, Laetitia, Pauporté, Iris, Faure-Mercier, Celine, Paget-Bailly, Sophie, Henriques, Julie, and Grouin, Jean Marie

Published
2019
Full Text
View/download PDF

11. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

Author

Trédan, O., Wang, Q., Pissaloux, D., Cassier, P., de la Fouchardière, A., Fayette, J., Desseigne, F., Ray-Coquard, I., de la Fouchardière, C., Frappaz, D., Heudel, P.-E., Bonneville-Levard, A., Fléchon, A., Sarabi, M., Guibert, P., Bachelot, T., Pérol, M., You, B., Bonnin, N., Collard, O., Leyronnas, C., Attignon, V., Baudet, C., Sohier, E., Villemin, J.-P., Viari, A., Boyault, S., Lantuejoul, S., Paindavoine, S., Treillleux, I., Rodriguez, C., Agrapart, V., Corset, V., Garin, G., Chabaud, S., Pérol, D., and Blay, J.-Y.

Published
2019
Full Text
View/download PDF

12. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study

Author

Joly, F., Ahmed-Lecheheb, D., Kalbacher, E., Heutte, N., Clarisse, B., Grellard, J.M., Gernier, F., Berton-Rigaud, D., Tredan, O., Fabbro, M., Savoye, A.M., Kurtz, J.E., Alexandre, J., Follana, P., Delecroix, V., Dohollou, N., Roemer-Becuwe, C., De Rauglaudre, G., Lortholary, A., Prulhiere, K., Lesoin, A., Zannetti, A., N’Guyen, S., Trager-Maury, S., Chauvenet, L., Abadie Lacourtoisie, S., Gompel, A., Lhommé, C., Floquet, A., and Pautier, P.

Published
2019
Full Text
View/download PDF

15. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Buck, M, Dean, A, Friedlander, M L, Goh, J C, Harnett, P, Kichenadasse, G, Scott, C L, Denys, H, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Welch, S, Floquet, A, Gladieff, L, Joly, F, Leary, A, Lortholary, A, Lotz, J, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Pignata, S, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Herraez, A Casado, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Clamp, A, Drew, Y, Gabra, H G, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Aghajanian, C, Armstrong, D K, Birrer, M J, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, Mutch, D G, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M, Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Isaacson, Jeff, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, and Ledermann, Jonathan A

Published
2017
Full Text
View/download PDF

16. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Author

Belin, L., Kamal, M., Mauborgne, C., Plancher, C., Mulot, F., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Ricci, F., Alt, M., Loirat, D., Sablin, M.-P., Paoletti, X., Servois, V., and Le Tourneau, C.

Published
2017
Full Text
View/download PDF

17. Compliance to genomic test recommendations to guide adjuvant chemotherapy decision‐making in the case of hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer, in real‐life settings

Author

Hequet, D., primary, Hajjaji, N., additional, Charafe‐Jauffret, E., additional, Boucrauta, A., additional, Dalenc, F., additional, Nicolai, V., additional, Lopez, J., additional, Tredan, O., additional, Deluche, E., additional, Fermeaux, V., additional, Tixier, L., additional, Cayre, A., additional, Menet, E., additional, Lerebours, F., additional, and Rouzier, R., additional

Published
2023
Full Text
View/download PDF

18. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

Author

Trédan, O., Follana, P., Moullet, I., Cropet, C., Trager-Maury, S., Dauba, J., Lavau-Denes, S., Diéras, V., Béal-Ardisson, D., Gouttebel, M., Orfeuvre, H., Stefani, L., Jouannaud, C., Bürki, F., Petit, T., Guardiola, E., Becuwe, C., Blot, E., Pujade-Lauraine, E., and Bachelot, T.

Published
2016
Full Text
View/download PDF

19. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Author

Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., Mousseau, M., Dauba, J., Del Piano, F., Desmoulins, I., Coussy, F., Madranges, N., Grenier, J., Bidard, F.C., Proudhon, C., MacGrogan, G., Orsini, C., Pulido, M., and Gonçalves, A.

Published
2016
Full Text
View/download PDF

22. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients

Author

Trédan, O., Ménétrier-Caux, C., Ray-Coquard, I., Garin, G., Cropet, C., Verronèse, E., Bachelot, T., Rebattu, P., Heudel, P.E., Cassier, P., Chabaud, S., Croughs, T., Dupont, P., Cadore, A.C., Clapisson, G., Delgado, A., Bardin-dit-Courageot, C., Rigal, C., N'Kodia, A., Gilles-Afchain, L., Morre, M., Pérol, D., Blay, J.Y., and Caux, C.

Published
2015
Full Text
View/download PDF

23. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Author

Bonnefoi, H., Jacot, W., Saghatchian, M., Moldovan, C., Venat-Bouvet, L., Zaman, K., Matos, E., Petit, T., Bodmer, A., Quenel-Tueux, N., Chakiba, C., Vuylsteke, P., Jerusalem, G., Brain, E., Tredan, O., Messina, C.G.M., Slaets, L., and Cameron, D.

Published
2015
Full Text
View/download PDF

24. 46P Long-term residual chemotherapy-induced peripheral neuropathy (CIPN) and relationship with single nucleotide polymorphisms (SNPs) in ovarian cancer patients free of disease in the GINECO Vivrovaire study

Author

Zenatri, M., primary, Perennec, T., additional, Michon, C., additional, Gernier, F., additional, Grellard, J-M., additional, Kalbacher, E., additional, Tredan, O., additional, Augereau, P., additional, Pautier, P., additional, Fey, L., additional, Joly Lobbedez, F., additional, and Frenel, J-S., additional

Published
2023
Full Text
View/download PDF

25. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Author

Nabholtz, J.M., Abrial, C., Mouret-Reynier, M.A., Dauplat, M.M., Weber, B., Gligorov, J., Forest, A.M., Tredan, O., Vanlemmens, L., Petit, T., Guiu, S., Van Praagh, I., Jouannaud, C., Dubray-Longeras, P., Tubiana-Mathieu, N., Benmammar, K.E., Kullab, S., Bahadoor, M.R.K., Radosevic-Robin, N., Kwiatkowski, F., Desrichard, A., Cayre, A., Uhrhammer, N., Chalabi, N., Chollet, P., and Penault-Llorca, F.

Published
2014
Full Text
View/download PDF

27. EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial

Author

Perrier, L, primary, Tredan, O, additional, Morelle, M, additional, Penel, N, additional, Fournel, P, additional, Greillier, L, additional, Ghiringhelli, F, additional, Tosi, D, additional, Bertucci, F, additional, Campone, M, additional, Delord, JP, additional, Pouessel, D, additional, Garin, G, additional, Chabaud, S, additional, Gomez-Roca, C, additional, Pannier, D, additional, Brahmi, M, additional, Fabbro, M, additional, Garcia, ME, additional, Ray-Coquard, I, additional, Viala, M, additional, Italiano, A, additional, Cassier, P, additional, Dufresne, A, additional, Attignon, V, additional, Treilleux, I, additional, Viari, A, additional, de la Motte Rouge, T, additional, Durando, X, additional, Perol, D, additional, and Blay, JY, additional

Published
2022
Full Text
View/download PDF

32. LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Author

Rugo, H.S., primary, Bardia, A., additional, Marmé, F., additional, Cortés, J., additional, Schmid, P., additional, Loirat, D., additional, Tredan, O., additional, Ciruelos, E.M., additional, Dalenc, F., additional, Gomez Pardo, P., additional, Jhaveri, K., additional, Delaney, R.J., additional, Valdez, T., additional, Wang, H., additional, Verret, W., additional, and Tolaney, S.M., additional

Published
2022
Full Text
View/download PDF

33. 213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)

Author

Arnedos, M., primary, Goncalves, A., additional, Pulido, M., additional, Lerebours, F., additional, Tredan, O., additional, Dalenc, F., additional, Guiu, S., additional, Mollon Grange, D., additional, Teixeira, L., additional, Levy, C., additional, Verret, B., additional, Dawood, H.A.S., additional, Augereau, P., additional, Deiana, L., additional, Ladoire, S., additional, Carola, E., additional, Mouret Reynier, M.A., additional, Guyonneau, C., additional, MacGrogan, G., additional, and Bonnefoi, H., additional

Published
2022
Full Text
View/download PDF

34. 1558MO Dissecting sexual health after breast cancer (BC) by longitudinal assessment of patient reported outcomes

Author

Franzoi, M.A., primary, Aupomerol, M., additional, Havas, J., additional, Hang, H., additional, Di Meglio, A., additional, Lambertini, M., additional, Massarotti, C., additional, Coutant, C., additional, Tredan, O., additional, Joly Lobbedez, F., additional, Cottu, P.H., additional, Soldato, D., additional, Mouret, M-A., additional, Tarpin, C., additional, Arnaud, A., additional, Fasse, L., additional, Everhard, S., additional, Martin, A-L., additional, Pistilli, B., additional, and Luis, I.V., additional

Published
2022
Full Text
View/download PDF

35. LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)

Author

Goetz, M.P., primary, Toi, M., additional, Huober, J., additional, Sohn, J., additional, Tredan, O., additional, Park, I.H., additional, Campone, M., additional, Chen, S.C., additional, Sanchez, L.M. Manso, additional, Paluch-Shimon, S., additional, van Hal, G., additional, Shahir, A., additional, Iwata, H., additional, and Johnston, S., additional

Published
2022
Full Text
View/download PDF

36. 1551O Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study

Author

Kabirian, R., primary, Havas, J., additional, Franzoi, M.A., additional, Coutant, C., additional, Tredan, O., additional, Levy, C., additional, Cottu, P.H., additional, Dhaini Merimeche, A., additional, Guillermet, S., additional, Ferrero, J-M., additional, Giacchetti, S., additional, Petit, T., additional, Dalenc, F., additional, Rouanet, P., additional, Querel, O., additional, Martin, A-L., additional, Pistilli, B., additional, Lambertini, M., additional, Luis, I.V., additional, and Di Meglio, A., additional

Published
2022
Full Text
View/download PDF

37. 1610P Humoral immune response to COVID-19 vaccination in patients with cancer: The ANRS0001S COV-POPART study

Author

Luong Nguyen, L.B., primary, Chalouni, M., additional, Loubet, P., additional, Dohollou, N., additional, Tredan, O., additional, Veyri, M., additional, Maakaroun-Vermesse, Z., additional, Ben Ghezala, I., additional, Fourn, E., additional, Merrien, D., additional, Cracowski, C., additional, Barquin, A., additional, Levier, A., additional, Wittkop, L., additional, Launay, O., additional, Blay, J-Y., additional, and Spano, J-P., additional

Published
2022
Full Text
View/download PDF

42. 730P Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA

Author

Beinse, G., Taly, V., Leary, A., Baures, A., Tredan, O., You, B., Rodrigues, M.J., Gladieff, L., Lacourtoisie, S. Abadie, Lefevre, L. Bengrine, Brachet, P-E., Lebreton, C., Kalbacher, E., Fournel, P., Frenel, J-S., Selle, F., Largillier, R., Laurent-Puig, P., Lobbedez, F. Joly, and Alexandre, J.

Published
2024
Full Text
View/download PDF

43. 372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database

Author

Pflumio, C., Carton, M., Debled, M., Cottu, P.H., Leheurteur, M., Dalenc, F., Jacot, W., Mailliez, A., Sauterey, B., Levy, C., Kaderbhai, C., Tredan, O., Gonçalves, A., Uwer, L., Robert, M., Bailleux, C., Cabel, L., Delaloge, S., Bosquet, L., and Petit, T.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results